“In the deal, PolyNovo will refine its NovoSorb polymer for the...

“In the deal, PolyNovo will refine its NovoSorb polymer for the prevention and treatment of cardiac and vascular disease, and tailor it to Medtronic's specially designed stents.PolyNovo CEO Dr Ian Griffiths said Medtronic had resources to deliver on a complex, multidisciplinary development program, combined with global reach in sales, marketing and distribution. "The real value for PolyNovo in this deal lies in milestone payments and the potential for royalties on sales of products," he said.Medtronic has a market capitalisation of US$71 billion with annual sales of $11 billion."It has taken almost a year since we commenced negotiations," Griffiths said. "The development relationship is a partnership. At PolyNovo, we will refine the polymer to best suite the stents that Medtronic is developing. Medtronic will then be responsible for all clinical and regulatory approvals. The deal is valid for the lifetime of the patents, once they are granted."

@jevalent, are we going back 18 years and could this be linked to Polynovo polymer?